Product
Eliglustat
Aliases
Cerdelga, CERDELGA, GZ385660
Name
Cerdelga
INN Name
eliglustat
FDA Approved
Yes
4 clinical trials
1 organization
5 indications
1 document
Indication
Gaucher DiseaseIndication
Gaucher's Disease Type IIndication
Gaucher's Disease Type IIIIndication
Solid TumorIndication
hematologic malignanciesClinical trial
An Open-label Study to Assess the Absorption Through the Mouth After Three Repeated 50 mg Doses of Eliglustat Solution, Separated by 2-hour Intervals, Held in the Mouth for 30 Seconds With Swishing But Without Ingestion, in Healthy SubjectsStatus: Completed, Estimated PCD: 2014-09-21
Clinical trial
A Randomized, Three-Period Crossover Study of Single and Repeated Doses for Three Different Strengths of Eliglustat in Healthy Adult, CYP2D6 Extensive and Poor MetabolizersStatus: Completed, Estimated PCD: 2018-03-26
Clinical trial
Open Label, Two Cohort (With and Without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients With Gaucher Disease Type 1 and Type 3Status: Active (not recruiting), Estimated PCD: 2025-11-20
Clinical trial
Phase ⅠStudy of GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Treating Patients With Advanced Relapsed or Refractory Hematological Malignancies and Previously Treated Solid TumorsStatus: Completed, Estimated PCD: 2023-11-30
Document
DailyMed Label: CerdelgaOrganization
Genzyme Corporation